Cognos Therapeutics
  • ABOUT
    • MISSION
    • BOARD of DIRECTORS
    • MANAGEMENT TEAM
    • NEURO-ONCOLOGY BOARD
    • OVARIAN CANCER CLINICAL ADVISORY BOARD
  • CLINICAL RELEVANCE
    • FOURTH MODALITY
  • PUBLICATIONS
  • NEWS
  • SHAREHOLDER PORTAL
    • SHAREHOLDER INFORMATION
  • CONTACT
Select Page
Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics  as Lead Regulatory Consultant

Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant

by cognosadminteam | February 27, 2019 | News

Dr. Susan Alpert, MD, PhD, has been named, Lead Regulatory Consultant for Cognos Therapeutics, Inc. Dr. Alpert is considered one of the top U.S. regulatory experts.

Cognos’ SINNAIS Smart Implantable Pump to Improve CAR T Cell Efficacy in Solid tumors

Cognos’ SINNAIS Smart Implantable Pump to Improve CAR T Cell Efficacy in Solid tumors

by cognosadminteam | January 12, 2018 | News

Cognos Therapeutics believes its SINNAIS implantable pump can increase efficacy of CAR T therapies for the treatment of leukemia.

Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region.

Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region.

by cognosadminteam | July 13, 2017 | News

Cognos Therapeutics plans to conduct a 20-patient human clinical trial for direct delivery of Herceptin using the Sinnais implantable pump.

Dr. Francis Ali-Osman

Dr. Francis Ali-Osman

by cognosadminteam | September 16, 2016 | News

Dr. Francis Ali-Osman speaks at the Hancock Symposium at Westminster Collage on the state of cancer research and treatment.

FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.

FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.

by cognosadminteam | March 28, 2015 | News

Cognos Therapeutics’ Sinnais drug delivery technology is poised to meet the need for Companion Diagnostic modalities.

Recent Posts

  • Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant
  • Cognos’ SINNAIS Smart Implantable Pump to Improve CAR T Cell Efficacy in Solid tumors
  • Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region.
  • Dr. Francis Ali-Osman
  • FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.

Recent Comments

    Archives

    • February 2019
    • January 2018
    • July 2017
    • September 2016
    • March 2015

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Cognos Therapeutics, Inc.

    10604 S La Cienega Blvd.
    Inglewood, CA 90304
    T: 310-641-2700
    F: 310-641-2702
    E: info@cognosthx.com

    ADDITIONAL INFO

    Privacy Policy
    Terms of Use
    Website Design by IDG-Partners